Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/216555
Title: Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation
Author: Donadeu, Laura
Gomez Olles, Susana
Casanova, Franc
Torija, Alba
Lopez Meseguer, Manuel
Boada Pérez, Meritxell
Kervella, Delphine
Crespo, Elena
Carrera Muñoz, Claudia
Campos Varela, Isabel
Castells, Lluís
Cortese, Maria F.
Esperalba, Juliana
Fernández Naval, Candela
Quintero, Jesús
Muñoz, Marina
Agüero, Fernando
González-Costello, José
Lladó, Laura
Favà, Alexandre
Cañas, Laura
Hoz Caballero, María Del Mar De La
Meneghini, Maria
Torres, Irina B.
Juvé, Mariona
Hafkamp, Fmj
Vila, Marta
Robles, Alba G.
Buzón, Maria José
Toapanta, Nestor
Zúñiga, José Miguel
Monforte, Víctor
Saez Giménez, Berta
Len, Oscar
Arcos, Ibai Los
Miret, Enric
Ariceta, Gema
Pardo, Emma
Martínez, Xavier
Moreso, Francesc
Bestard Matamoros, Oriol
Keywords: SARS-CoV-2
Vacunació
Trasplantament d'òrgans
SARS-CoV-2
Vaccination
Transplantation of organs
Issue Date: 8-Oct-2024
Publisher: Frontiers Media SA
Abstract: Introduction Solid organ transplant (SOT) recipients display weak seroconversion and neutralizing antibody (NAb) responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and remain at risk of severe coronavirus disease 2019 (COVID-19). While B-cell memory is the hallmark of serological immunity, its role in driving successful vaccine responses and providing immune protection in SOT patients remains unclear.Methods We investigated the function and interplay of SARS-CoV-2-specific memory B cells (mBc), different cytokineproducing T cells, and cross-reactive NAb in driving seroconversion and protection against COVID-19 in two cohorts. First, we studied a large cohort of 148 SOT recipients and 32 immunocompetent individuals who underwent several vaccinations. Subsequently, we assessed 25 SOT patients participating in a randomized controlled trial to compare two different immunosuppressive strategies for allowing successful seroconversion and memory-cell responses after booster vaccination.Results We corroborate previous findings that B- and T-cell memory responses are weaker and more delayed in SOT patients than in immunocompetent (IC) individuals; however, within the SOT cohort, we found that these responses are relatively stronger and more robust in patients not receiving mycophenolate mofetil (MMF)-based therapies. Anti- spike IgG titers strongly correlated with RBD-specific IgG-producing mBc, with both displaying broad viral cross reactivity. Prebooster SARS-CoV-2-specific mBc and IL-2- producing T cells accurately predicted Nab seroconversion (AUC, 0.828) and protection against severe COVID-19. While switching unresponsive SOT patients from calcineurin inhibitors (CNI)/MMF to a low-exposure CNI/mTOR-i regimen favored wider SARS-CoV-2-specific immune responses after a fourth booster vaccination, preformed RBD-specific mBc predicted NAb seroconversion.Discussion Our study adds new insights into the pathobiology of immune memory and highlights the pivotal role of SARS-CoV-2-specific mBc in promoting immune protection inSOT patients.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2024.1463769
It is part of: Frontiers in Immunology, 2024, vol. 15
URI: https://hdl.handle.net/2445/216555
Related resource: https://doi.org/10.3389/fimmu.2024.1463769
ISSN: 1664-3224
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
fimmu-15-1463769.pdf5.49 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons